Says “extremely pleased” with the results of the Amtagvi trial. Says “truly excited” about U.S. commercial launch. Says expects “strong” market access to Amtagvi. Comments taken from a conference call about Amtagvi’s accelerated approval from the FDA.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IOVA:
- Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024
- Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma
- Iovance Biotherapeutics call volume above normal and directionally bullish
- Unusually active option classes on open January 26th
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
